Predictions for the future of kallikrein-related peptidases in molecular diagnostics

References

• Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun 2000;276(1):125-33
   PubMed Web of Science ®Google Scholar
• Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17(2):159-63
   PubMedGoogle Scholar
• Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40(12):4658-62
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909-16
   PubMed Web of Science ®Google Scholar
• Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37(9):1618-25
   PubMed Web of Science ®Google Scholar
• Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-6
   PubMed Web of Science ®Google Scholar
• Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem 2008;54(10):1600-7
   PubMed Web of Science ®Google Scholar
• Kontos CK, Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin Chem Lab Med 2012;50(11):1877-91
   PubMed Web of Science ®Google Scholar
• Mavridis K, Scorilas A. Prognostic value and biological role of the kallikrein-related peptidases in human malignancies. Future Oncol 2010;6(2):269-85
   PubMed Web of Science ®Google Scholar
• Mavridis K, Avgeris M, Scorilas A. Targeting kallikrein-related peptidases in prostate cancer. Expert Opin Ther Targets 2014;18(4):365-83
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci 2012;33(12):623-34
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Lai J, Clements JA. Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus. Endocr Rev 2010;31(4):407-46
   PubMed Web of Science ®Google Scholar
• Emami N, Diamandis EP. New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol Oncol 2007;1(3):269-87
   PubMed Web of Science ®Google Scholar
• Pasic MD, Olkhov E, Bapat B, Yousef GM. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. Biol Chem 2012;393(5):319-30
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G, Diamandis EP. Functional roles of human kallikrein-related peptidases. J Biol Chem 2009;284(48):32989-94
   PubMed Web of Science ®Google Scholar
• Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2(5):257-80
   PubMed Web of Science ®Google Scholar
• Scarisbrick IA, Yoon H, Panos M, et al. Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol 2012;22(5):709-22
   PubMed Web of Science ®Google Scholar
• Yousef GM, Kishi T, Diamandis EP. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 2003;329(1-2):1-8
   PubMed Web of Science ®Google Scholar
• Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem 1999;274(42):30033-40
   PubMed Web of Science ®Google Scholar
• Brattsand M, Stefansson K, Lundh C, et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol 2005;124(1):198-203
   PubMed Web of Science ®Google Scholar
• Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol 2004;122(5):1235-44
   PubMed Web of Science ®Google Scholar
• Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 2007;18(9):3607-19
   PubMed Web of Science ®Google Scholar
• Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012;4(127):127rv123
   Web of Science ®Google Scholar
• Leung F, Diamandis EP, Kulasingam V. From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade. Biomark Med 2012;6(5):613-25
   PubMed Web of Science ®Google Scholar
• Schroder FH. Landmarks in prostate cancer screening. BJU Int 2012(110 Suppl 1):3-7
   PubMedGoogle Scholar
• Stamey TA, Graves HC, Wehner N, et al. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149(4):787-92
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Djavan WB, Hammerer P, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382-90
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156-61
   PubMed Web of Science ®Google Scholar
• Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001;23(1):181-6
   PubMed Web of Science ®Google Scholar
• Marta GN, Hanna SA, Fernandes da Silva JL, Carvalho Hde A. Screening for prostate cancer: an updated review. Expert Rev Anticancer Ther 2013;13(1):101-8
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Roobol MJ, Lilja H. Screening for prostate cancer: early detection or overdetection? Annu Rev Med 2012;63:161-70
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-19
   PubMed Web of Science ®Google Scholar
• Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-8
   PubMed Web of Science ®Google Scholar
• Carter HB. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale. BJU Int 2013;112(5):543-7
   PubMed Web of Science ®Google Scholar
• Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155(11):762-71
   PubMed Web of Science ®Google Scholar
• Prensner JR, Chinnaiyan AM, Srivastava S. Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 2012;29(7):645-52
   PubMed Web of Science ®Google Scholar
• Melichar B. PSA, PCA3 and the phi losophy of prostate cancer management. Clin Chem Lab Med 2013;51(4):707-12
   PubMed Web of Science ®Google Scholar
• Stephan C, Rittenhouse H, Cammann H, et al. New markers and multivariate models for prostate cancer detection. Anticancer Res 2009;29(7):2589-600
   PubMed Web of Science ®Google Scholar
• Stephan C, Jung K, Semjonow A, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013;59(1):280-8
   PubMed Web of Science ®Google Scholar
• Schmitt M, Sommerhoff CP, Fritz H, Magdolen V. Introduction to Volume 2: Kallikrein-related peptidases. novel cancer-related biomarkers. De Gruyter; Berlin, Germany: 2012
   Google Scholar
• Avgeris M, Mavridis K, Scorilas A. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol Chem 2012;393(5):301-17
   PubMed Web of Science ®Google Scholar
• Dorn J, Bayani J, Yousef GM, et al. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies. Thromb Haemost 2013;110(3):408-22
   PubMed Web of Science ®Google Scholar
• Kontos CK, Mavridis K, Talieri M, Scorilas A. Kallikrein-related peptidases (KLKs) in gastrointestinal cancer: mechanistic and clinical aspects. Thromb Haemost 2013;110(3):450-7
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Aziz K, Panayiotidis MI, Georgakilas AG. Molecular markers for cancer prognosis and treatment: have we struck gold? Cancer Lett 2012;327(1-2):142-52
   PubMed Web of Science ®Google Scholar
• Gupta A, Roobol MJ, Savage CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 2010;103(5):708-14
   PubMed Web of Science ®Google Scholar
• Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010;28(15):2493-8
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Roobol MJ, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res 2010;16(12):3232-9
   PubMed Web of Science ®Google Scholar
• Carlsson SV, Peltola MT, Sjoberg D, et al. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int 2013;112(5):602-9
   PubMed Web of Science ®Google Scholar
• Voigt JD, Zappala SM, Vaughan ED, Wein AJ. The Kallikrein Panel for prostate cancer screening: its economic impact. Prostate 2014;74(3):250-9
   PubMed Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15(5):1787-93
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol 2003;21(6):1035-43
   PubMed Web of Science ®Google Scholar
• Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63(4):807-11
   PubMed Web of Science ®Google Scholar
• El Sherbini MA, Sallam MM, Shaban EA, El-Shalakany AH. Diagnostic value of serum kallikrein-related peptidases 6 and 10 versus CA125 in ovarian cancer. Int J Gynecol Cancer 2011;21(4):625-32
   PubMed Web of Science ®Google Scholar
• Koh SC, Huak CY, Lutan D, et al. Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer. J Gynecol Oncol 2012;23(3):175-81
   PubMed Web of Science ®Google Scholar
• Shih Ie M, Salani R, Fiegl M, et al. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 2007;105(2):501-7
   PubMed Web of Science ®Google Scholar
• White NM, Mathews M, Yousef GM, et al. Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone. Cancer Biomark 2009;5(6):279-87
   PubMed Web of Science ®Google Scholar
• Zheng Y, Katsaros D, Shan SJ, et al. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res 2007;13(23):6984-92
   PubMed Web of Science ®Google Scholar
• Dorn J, Schmitt M, Kates R, et al. Primary tumor levels of human tissue kallikreins affect surgical success and survival in ovarian cancer patients. Clin Cancer Res 2007;13(6):1742-8
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Li L, Zheng Y, et al. Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer 2008;99(7):1103-13
   PubMed Web of Science ®Google Scholar
• Planque C, Li L, Zheng Y, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008;14(5):1355-62
   PubMed Web of Science ®Google Scholar
• Planque C, Choi YH, Guyetant S, et al. Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer. Clin Chem 2010;56(6):987-97
   PubMed Web of Science ®Google Scholar
• Talieri M, Li L, Zheng Y, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer 2009;100(10):1659-65
   PubMed Web of Science ®Google Scholar
• Kotorashvili A, Ramnauth A, Liu C, et al. Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens. PLoS One 2012;7(4):e34683
   Web of Science ®Google Scholar
• Allegra A, Alonci A, Campo S, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 2012;41(6):1897-912
   PubMed Web of Science ®Google Scholar
• Liu A, Xu X. MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. Methods Mol Biol 2011;724:259-67
   PubMedGoogle Scholar
• White NM, Youssef YM, Fendler A, et al. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer. Biol Chem 2012;393(5):379-89
   PubMed Web of Science ®Google Scholar
• White NM, Chow TF, Mejia-Guerrero S, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer 2010;102(8):1244-53
   PubMed Web of Science ®Google Scholar
• White NM, Bui A, Mejia-Guerrero S, et al. Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs. Biol Chem 2010;391(4):411-23
   PubMed Web of Science ®Google Scholar
• Yousef GM, White NM. Kallikrein-related peptidases. Volume 2, Chapter 8 microRNAs: a new control mechanism for kallikrein-related peptidases in kidney and other cancers. De Gruyter; Berlin, Germany: 2012. p. 167-82
   Google Scholar
• Mavridis K, Stravodimos K, Scorilas A. Quantified KLK15 gene expression levels discriminate prostate cancer from benign tumors and constitute a novel independent predictor of disease progression. Prostate 2013;73(11):1191-201
   PubMed Web of Science ®Google Scholar
• Mavridis K, Stravodimos K, Scorilas A. Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 2013;59(1):261-9
   PubMed Web of Science ®Google Scholar
• Rabien A, Fritzsche FR, Jung M, et al. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy. Int J Cancer 2010;127(10):2386-94
   PubMed Web of Science ®Google Scholar
• Lin ZY, Huang YQ, Zhang YQ, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer 2014;135(3):541-50
   PubMed Web of Science ®Google Scholar
• Pampalakis G, Diamandis EP, Sotiropoulou G. The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem 2006;387(6):795-9
   PubMed Web of Science ®Google Scholar
• Olkhov-Mitsel E, Van der Kwast T, Kron KJ, et al. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics 2012;7(9):1037-45
   PubMed Web of Science ®Google Scholar
• Bayani J, Diamandis EP. The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6). Clin Chem Lab Med 2012;50(2):211-33
   Web of Science ®Google Scholar
• Diamandis EP, Scorilas A, Kishi T, et al. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. Clin Biochem 2004;37(3):230-7
   PubMed Web of Science ®Google Scholar
• Diamandis EP, Yousef GM, Petraki C, Soosaipillai AR. Human kallikrein 6 as a biomarker of alzheimer’s disease. Clin Biochem 2000;33(8):663-7
   PubMed Web of Science ®Google Scholar
• Wennstrom M, Surova Y, Hall S, et al. Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One 2013;8(1):e53250
   PubMed Web of Science ®Google Scholar
• Mitsui S, Okui A, Uemura H, et al. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer’s disease. Ann N Y Acad Sci 2002;977:216-23
   PubMed Web of Science ®Google Scholar
• Menendez-Gonzalez M, Castro-Santos P, Suarez A, et al. Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer’s disease. J Alzheimers Dis 2008;14(1):59-67
   PubMed Web of Science ®Google Scholar
• Menendez-Gonzalez M, Castro-Santos P, Calatayud MT, et al. Plasmatic level of neurosin predicts outcome of mild cognitive impairment. Int Arch Med 2008;1(1):11
   PubMedGoogle Scholar
• Phipps HW, Longo LM, Blaber SI, et al. Kallikrein-related peptidase 6: a biomarker for traumatic brain injury in the rat. Brain Inj 2013;27(13-14):1698-706
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Ottervald J, Nilsson KC, et al. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 2009;71(6):670-81
   PubMed Web of Science ®Google Scholar
• Martinez-Morillo E, Diamandis A, Romaschin AD, Diamandis EP. Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage. PLoS One 2012;7(9):e45676
   Web of Science ®Google Scholar
• Scarisbrick IA, Linbo R, Vandell AG, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008;389(6):739-45
   PubMed Web of Science ®Google Scholar
• Hebb AL, Bhan V, Wishart AD, et al. Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr Drug Discov Technol 2010;7(2):137-40
   PubMedGoogle Scholar
• Kroksveen AC, Guldbrandsen A, Vedeler C, et al. Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls. Acta Neurol Scand Suppl 2012(195):90-6
   PubMedGoogle Scholar
• Kroksveen AC, Aasebo E, Vethe H, et al. Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. J Proteomics 2013;78:312-25
   PubMed Web of Science ®Google Scholar
• Harris VK, Diamanduros A, Good P, et al. Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis. Neurobiol Dis 2010;40(1):331-9
   PubMed Web of Science ®Google Scholar
• El Annan J, Jiang G, Wang D, et al. Elevated immunoglobulin to tissue KLK11 in patients with Sjogren syndrome. Cornea 2013;32(5):e90-3
   PubMed Web of Science ®Google Scholar
• Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25(2):141-2
   PubMed Web of Science ®Google Scholar
• Eissa A, Cretu D, Soosaipillai A, et al. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. Clin Chem Lab Med 2013;51(2):317-25
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol 2007;156(5):875-83
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Kuk C, et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol 2007;16(6):513-19
   PubMed Web of Science ®Google Scholar
• Batra J, O’Mara T, Patnala R, et al. Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases. Biol Chem 2012;393(12):1365-90
   PubMed Web of Science ®Google Scholar
• Izumi A, Iijima Y, Noguchi H, et al. Genetic variations of human neuropsin gene and psychiatric disorders: polymorphism screening and possible association with bipolar disorder and cognitive functions. Neuropsychopharmacology 2008;33(13):3237-45
   PubMed Web of Science ®Google Scholar
• Lose F, Batra J, O’Mara T, et al. Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol Oncol 2013;31(5):635-43
   PubMed Web of Science ®Google Scholar
• Lose F, Srinivasan S, O’Mara T, et al. Genetic association of the KLK4 locus with risk of prostate cancer. PLoS One 2012;7(9):e44520
   Web of Science ®Google Scholar
• Nam RK, Zhang WW, Trachtenberg J, et al. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 2003;21(12):2312-19
   PubMed Web of Science ®Google Scholar
• Van den Broeck T, Joniau S, Clinckemalie L, et al. The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. Biomed Res Int 2014;2014:627510
   PubMed Web of Science ®Google Scholar
• Gilgunn S, Conroy PJ, Saldova R, et al. Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol 2013;10(2):99-107
   PubMed Web of Science ®Google Scholar
• Kuzmanov U, Smith CR, Batruch I, et al. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics 2012;12(6):799-809
   PubMed Web of Science ®Google Scholar
• Talieri M, Devetzi M, Scorilas A, et al. Human kallikrein-related peptidase 12 (KLK12) splice variants expression in breast cancer and their clinical impact. Tumour Biol 2012;33(4):1075-84
   PubMedGoogle Scholar
• Xu CH, Zhang Y, Yu LK. The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer. Tumour Biol 2014. [Epub ahead of print]
   Google Scholar
• Jiao X, Lu HJ, Zhai MM, et al. Overexpression of kallikrein gene 10 is a biomarker for predicting poor prognosis in gastric cancer. World J Gastroenterol 2013;19(48):9425-31
   PubMed Web of Science ®Google Scholar
• Shinoda Y, Kozaki K, Imoto I, et al. Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci 2007;98(7):1078-86
   PubMed Web of Science ®Google Scholar
• Talieri M, Zoma M, Devetzi M, et al. Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors. Tumour Biol 2012;33(5):1375-83
   PubMedGoogle Scholar